Floatz Rating
B57/100
Confidence
Indicative
Sponsor
Second Affiliated Hospital of Nanchang University
Modality
Small molecule
Development Phase
Phase 2
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
42Moderate confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT07398599CT.gov Double-Dose Third-Generation EGFR-TKI Plus Bevacizumab and Intrathecal Chemotherapy for Refractory Leptomeningeal Metastatic NSCLC: A Phase II Study | — | Recruiting | — | — | — |
NCT06304441CT.gov Intra-pemetrexed Plus Third-generation Small Molecule TKI Drugs (e.g. 'Osimertinib') Versus Third-generation Small Molecule TKI Drugs Alone for Leptomeningeal Metastasis From Epidermal Growth Factor Receptor Mutation-Positive Non-Small-cell Lung Cancer | — | Recruiting | — | — | — |
NCT04233021CT.gov Study of Osimertinib in Patients with a Lung Cancer with Brain or Leptomeningeal Metastases with EGFR Mutation | — | Completed | — | — | — |
NCT04148898CT.gov Osimertinib With or Without Bevacizumab for EGFR- Mutant Non-small Cell Lung Cancer With Leptomeningeal Metastasis | — | Unknown | — | — | — |
NCT04425681CT.gov Osimertinib With Bevacizumab for Leptomeningeal Metastasis From EGFR-mutation Non-Small Cell Lung Cancer | — | Unknown | — | — | — |
NCT03257124CT.gov Study of AZD9291 in NSCLC Patients Harboring T790M Mutation Who Failed EGFR TKI and With Brain and/or LMS | — | Unknown | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
81High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Neoplastic Meningitis
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Osimertinib (this asset) | Second Affiliated Hospital of Nanchang University | P2 | B · 57 |
| Cytarabine | Fudan University | P4 | BBB |
| Dexasone | Shanghai Cancer Hospital, China | P2 | B |
| Lorlatinib | Guangdong Association of Clinical Trials | P4 | B |
| Durvalumab | Hui Bu | P4 | B |
| Methotrexate | The First Affiliated Hospital with Nanjing Medical University | P4 | B |
| Cis-Diamminedichloroplatinum Ii | Guangzhou Medical University | P2 | B |
| Etoposide | Guangzhou Medical University | P2 | B |
| Cyclophosphamide | Medical College of Wisconsin | P2 | B |
+39 more in the Neoplastic Meningitis cohort
Other indications for Osimertinib
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Non-Small Cell Lung Carcinoma | — | P4 | BB · 71 |
| Lung Adenocarcinoma | — | P2 | BB · 69 |
| Hepatocellular Carcinoma | — | P3 | BB · 65 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Osimertinib in Neoplastic Meningitis. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/osimertinib-neoplastic-meningitis
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →